Goldman Sachs
ARIA

Goldman Sachs’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Goldman Sachs’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-392,700
Closed -$4.88M – 7245
2016
Q4 		$4.88M Buy
392,700
+12,900
+3% +$155K ﹤0.01% 3074
2016
Q3 		$5.2M Buy
379,800
+360,200
+1,838% +$3.62M ﹤0.01% 3022
2016
Q2 		$145K Sell
19,600
-86,300
-81% -$647K ﹤0.01% 5917
2016
Q1 		$677K Buy
105,900
+32,300
+44% +$181K ﹤0.01% 4439
2015
Q4 		$460K Sell
73,600
-24,100
-25% -$158K ﹤0.01% 4996
2015
Q3 		$571K Sell
97,700
-690,500
-88% -$5.32M ﹤0.01% 5007
2015
Q2 		$6.52M Sell
788,200
-268,400
-25% -$2.37M ﹤0.01% 2709
2015
Q1 		$8.71M Sell
1,056,600
-542,300
-34% -$4.01M ﹤0.01% 2412
2014
Q4 		$11M Sell
1,598,900
-49,600
-3% -$310K ﹤0.01% 2273
2014
Q3 		$8.9M Buy
1,648,500
+862,800
+110% +$5.04M ﹤0.01% 2457
2014
Q2 		$5M Buy
785,700
+488,700
+165% +$3.36M ﹤0.01% 3035
2014
Q1 		$2.39M Sell
297,000
-314,100
-51% -$2.45M ﹤0.01% 3804
2013
Q4 		$4.17M Buy
611,100
+441,000
+259% +$2.38M ﹤0.01% 3285
2013
Q3 		$3.13M Sell
170,100
-11,400
-6% -$221K ﹤0.01% 3449
2013
Q2 		$3.17M Buy
+181,500
New +$3.22M ﹤0.01% 3219

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Goldman Sachs's ARIA Position: Q1 2017 in Review

Goldman Sachs sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 1,394,100 shares — an estimated $17.3M sold.

Goldman Sachs first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $149M in Q3 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Goldman Sachs reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Goldman Sachs sold 1,394,100 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $17.3M.
  • Goldman Sachs first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • Goldman Sachs's Ariad Pharmaceuticals Inc position peaked at $149M in Q3 2013.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Goldman Sachs's 13F filing for Q1 2017, filed 15 May 2017.